138 related articles for article (PubMed ID: 3412323)
21. Phenotyping polymorphic drug metabolism in the French Caucasian population.
Jacqz E; Dulac H; Mathieu H
Eur J Clin Pharmacol; 1988; 35(2):167-71. PubMed ID: 3191936
[TBL] [Abstract][Full Text] [Related]
22. Relationship between oxidative metabolism of 2-acetylaminofluorene, debrisoquine, bufuralol, and aldrin in human liver microsomes.
McManus ME; Boobis AR; Minchin RF; Schwartz DM; Murray S; Davies DS; Thorgeirsson SS
Cancer Res; 1984 Dec; 44(12 Pt 1):5692-7. PubMed ID: 6498831
[TBL] [Abstract][Full Text] [Related]
23. Polymorphism of debrisoquine and mephenytoin hydroxylation among Estonians.
Kiivet RA; Svensson JO; Bertilsson L; Sjöqvist F
Pharmacol Toxicol; 1993 Feb; 72(2):113-5. PubMed ID: 8474964
[TBL] [Abstract][Full Text] [Related]
24. Pharmacogenetics of dextromethorphan O-demethylation in man.
Küpfer A; Schmid B; Pfaff G
Xenobiotica; 1986 May; 16(5):421-33. PubMed ID: 3739367
[TBL] [Abstract][Full Text] [Related]
25. Population studies of polymorphism in drug oxidation and its relevance to carcinogenesis.
Ritchie JC; Idle JR
IARC Sci Publ; 1982; (39):381-94. PubMed ID: 7152615
[TBL] [Abstract][Full Text] [Related]
26. Disposition of clozapine in man: lack of association with debrisoquine and S-mephenytoin hydroxylation polymorphisms.
Dahl ML; Llerena A; Bondesson U; Lindström L; Bertilsson L
Br J Clin Pharmacol; 1994 Jan; 37(1):71-4. PubMed ID: 8148222
[TBL] [Abstract][Full Text] [Related]
27. Animal modelling of human polymorphic drug oxidation--the metabolism of debrisoquine and phenacetin in rat inbred strains.
Al-Dabbagh SG; Idle JR; Smith RL
J Pharm Pharmacol; 1981 Mar; 33(3):161-4. PubMed ID: 6116757
[TBL] [Abstract][Full Text] [Related]
28. [Pharmacogenetics of antidepressant metabolism. Value of the debrisoquin test].
Baumann P
Encephale; 1986; 12(4):143-8. PubMed ID: 3792273
[TBL] [Abstract][Full Text] [Related]
29. Lack of relationship between glibenclamide metabolism and debrisoquine or mephenytoin hydroxylation phenotypes.
Dahl-Puustinen ML; Alm C; Bertilsson L; Christenson I; Ostman J; Thunberg E; Wikström I
Br J Clin Pharmacol; 1990 Sep; 30(3):476-80. PubMed ID: 2121211
[TBL] [Abstract][Full Text] [Related]
30. [Interindividual differences in the reaction to drugs and poisons].
Meyer UA
Ther Umsch; 1992 Feb; 49(2):97-101. PubMed ID: 1553631
[TBL] [Abstract][Full Text] [Related]
31. Mephenytoin and sparteine oxidation: genetic polymorphisms in Denmark.
Drøhse A; Bathum L; Brøsen K; Gram LF
Br J Clin Pharmacol; 1989 May; 27(5):620-5. PubMed ID: 2757884
[TBL] [Abstract][Full Text] [Related]
32. Metoprolol and mephenytoin oxidation polymorphisms in Far Eastern Oriental subjects: Japanese versus mainland Chinese.
Horai Y; Nakano M; Ishizaki T; Ishikawa K; Zhou HH; Zhou BI; Liao CL; Zhang LM
Clin Pharmacol Ther; 1989 Aug; 46(2):198-207. PubMed ID: 2758729
[TBL] [Abstract][Full Text] [Related]
33. Mephenytoin and sparteine pharmacogenetics in Canadian Caucasians.
Inaba T; Jurima M; Nakano M; Kalow W
Clin Pharmacol Ther; 1984 Nov; 36(5):670-6. PubMed ID: 6488688
[TBL] [Abstract][Full Text] [Related]
34. [Genetic polymorphism of oxidative drug metabolism. Therapeutic and toxicologic implications].
Eichelbaum M
Internist (Berl); 1983 Mar; 24(3):117-27. PubMed ID: 6135670
[No Abstract] [Full Text] [Related]
35. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin.
Bertilsson L; Lou YQ; Du YL; Liu Y; Kuang TY; Liao XM; Wang KY; Reviriego J; Iselius L; Sjöqvist F
Clin Pharmacol Ther; 1992 Apr; 51(4):388-97. PubMed ID: 1345344
[TBL] [Abstract][Full Text] [Related]
36. The debrisoquine/sparteine oxidation polymorphism: evidence of genetic heterogeneity among Ghanaians.
Woolhouse NM
Prog Clin Biol Res; 1986; 214():189-206. PubMed ID: 3725761
[No Abstract] [Full Text] [Related]
37. Metabolic oxidation of methaqualone in extensive and poor metabolisers of debrisoquine.
Oram M; Wilson K; Burnett D; Al-Dabbagh SG; Idle JR; Smith RL
Eur J Clin Pharmacol; 1982; 23(2):147-50. PubMed ID: 7140803
[TBL] [Abstract][Full Text] [Related]
38. Genetic polymorphism of S-mephenytoin 4'-hydroxylation.
Daniel HI; Edeki TI
Psychopharmacol Bull; 1996; 32(2):219-30. PubMed ID: 8783891
[TBL] [Abstract][Full Text] [Related]
39. Genetically determined polymorphisms in drug oxidation.
Jacqz E; Hall SD; Branch RA
Hepatology; 1986; 6(5):1020-32. PubMed ID: 3758933
[No Abstract] [Full Text] [Related]
40. Relationship between mephenytoin oxidation polymorphism and phenytoin, methylphenytoin and phenobarbitone hydroxylation assessed in a phenotyped panel of healthy subjects.
Schellens JH; van der Wart JH; Breimer DD
Br J Clin Pharmacol; 1990 Jun; 29(6):665-71. PubMed ID: 2378787
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
